\-\ Texto\\:\\ \ \(0\)\
\-\ patient\\ with\\ darkened\\,\\ thickened\\,\\ warm\\ skin\\ over\\ right\\ breast\\.\\ \\ skin\\ dimpling\\ present\\.\\ \\ adenopathy\\ present\\ in\\ right\\ axilla\\.\ \(0\)\
\-\ left\\ breast\\ and\\ axilla\\ normal\\.\\ \\ exam\\ otherwise\\ unremarkable\\.\ \(0\)\
\-\ this\\ patient\\ was\\ treated\\ with\\ antibiotics\\ and\\ failed\\ to\\ improve\\ with\\ therapy\\.\ \(0\)\
\-\ a\\ biopsy\\ was\\ done\\ when\\ the\\ patient\\ returned\\ without\\ resolution\\ of\\ disease\\.\ \(0\)\
\-\ pathology\\:\\ biopsy\\ showed\\ dermal\\ lymphatic\\ invasion\\ by\\ tumor\\ cells\\,\\ atypical\\ mitotic\\ figures\\ and\\ pleomorphic\\ tumor\\ cells\\ consistent\\ with\\ inflammatory\\ breast\\ cancer\\.\\ \ \(0\)\
\-\ the\\ patient\\ was\\ then\\ referred\\ for\\ an\\ nih\\ treatment\\ protocol\\.\ \(0\)\
\-\ neoadjuvant\\ chemotherapy\\ protocol\\ followed\\ by\\ mastectomy\\ and\\ local\\ radiation\\ therapy\\.\ \(0\)\
\-\ ct\\ of\\ chest\\ shows\\ skin\\ thickening\\ over\\ right\\ breast\\,\\ significant\\ enlargement\\ of\\ right\\ breast\\ compared\\ to\\ left\\.\\ \\ fat\\ streaking\\ within\\ the\\ right\\ breast\\.\ \(0\)\
\-\ mri\\ of\\ thoracic\\ spine\\ shows\\ abnormal\\ signal\\ intensity\\ at\\ t4\\ and\\ t7\\ consistent\\ with\\ metastases\\.\ \(0\)\
\-\ inflammatory\\ breast\\ cancer\\,\\ metastatic\\ to\\ thoracic\\ spine\\ \\(stage\\ iv\\)\ \(0\)\
\-\ inflammatory\\ breast\\ cancer\\ metastatic\\ \\-stage\\ iv\ \(0\)\
\-\ inflammatory\\ breast\\ cancer\\,\\ locally\\ advanced\\-stage\\ iii\ \(0\)\
\-\ acute\\ mastitis\\ and\\/or\\ cellulitis\ \(0\)\
\-\ diffuse\\ inflammation\\ by\\ lymphoma\\ \ \(0\)\
\-\ advanced\\ non\\-inflammatory\\ breast\\ cancer\ \(0\)\
\-\ 55\\ y\\/o\\ woman\\ seen\\ as\\ an\\ outpatient\\ for\\ possible\\ mastitis\\.\ \(1\)\
\-\ in\\ 2004\\,\\ approximately\\ 217\\,440\\ women\\ were\\ diagnosed\\ with\\ breast\\ cancer\\ and\\ approximately\\ 40\\,580\\ died\\ from\\ it\\.\\ \\ breast\\ cancer\\ is\\ the\\ leading\\ cause\\ of\\ death\\ in\\ women\\ in\\ the\\ u\\.s\\.\\ ages\\ 45\\-55\\.\ \(0\)\
\-\ inflammatory\\ breast\\ cancer\\ is\\ rare\\,\\ consisting\\ of\\ 1\\-5\\%\\ of\\ invasive\\ breast\\ cancers\\.\\ \\ it\\ is\\ rapidly\\ progressive\\ and\\ the\\ most\\ lethal\\ form\\ of\\ locally\\ advanced\\ breast\\ cancer\\.\\ \\ it\\ is\\ characterized\\ by\\ early\\ metastatic\\ spread\\.\\ \\ in\\ fact\\,\\ up\\ to\\ 1\\/3\\ of\\ patients\\ have\\ distant\\ metastases\\ at\\ the\\ time\\ of\\ diagnosis\\.\ \(0\)\
\-\ while\\ biopsy\\ tends\\ to\\ show\\ characteristic\\ dermal\\ lymphatic\\ invasion\\ by\\ tumor\\ cells\\,\\ which\\ create\\ tumor\\ emboli\\ that\\ facilitate\\ in\\ the\\ early\\ metastatic\\ spread\\,\\ diagnosis\\ is\\ basically\\ clinical\\.\\ \\ the\\ hallmark\\ of\\ inflammatory\\ breast\\ cancer\\ is\\ the\\ classic\\ peau\\ d\\‚\\Ä\\ôorange\\ skin\\ changes\\.\\ \\ the\\ classic\\ definition\\ is\\ \\‚\\Ä\\údiffuse\\ brawny\\ induration\\ of\\ the\\ skin\\ of\\ the\\ breast\\ with\\ an\\ erysipeloid\\ edge\\,\\ usually\\ without\\ underlying\\ palpable\\ mass\\.\\‚\\Ä\\ù1\\ \\ as\\ in\\ this\\ case\\,\\ patients\\ are\\ frequently\\ misdiagnosed\\ with\\ acute\\ mastitis\\ or\\ a\\ breast\\ abscess\\,\\ especially\\ if\\ lactating\\,\\ when\\ they\\ first\\ present\\.\\ \\ \ \(0\)\
\-\ while\\ bilateral\\ mammograms\\ are\\ recommended\\ for\\ all\\ patients\\ with\\ breast\\ cancer\\,\\ in\\ these\\ patients\\ ct\\ and\\ mri\\ and\\ performed\\ to\\ look\\ for\\ distant\\ metastases\\ to\\ differentiate\\ between\\ stage\\ iii\\ and\\ stage\\ iv\\ cancers\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ breast\\:\\ 0\\.14398702147303002\ \(0\)\
\-\ cancer\\:\\ 0\\.07428081227887601\ \(0\)\
\-\ mastitis\\:\\ 0\\.04772808062473759\ \(0\)\
\-\ inflammatory\\:\\ 0\\.042740133810461885\ \(0\)\
\-\ skin\\:\\ 0\\.03944866508700695\ \(0\)\
\-\ axilla\\:\\ 0\\.02876108211495328\ \(0\)\
\-\ locally\\:\\ 0\\.028226343484615665\ \(0\)\
\-\ dermal\\:\\ 0\\.027521519089462418\ \(0\)\
\-\ lymphatic\\:\\ 0\\.027307808692487254\ \(0\)\
\-\ metastases\\:\\ 0\\.02632739747627152\ \(0\)\
\-\ stage\\:\\ 0\\.026286305977848656\ \(0\)\
\-\ cancers\\:\\ 0\\.02476902297036948\ \(0\)\
\-\ cells\\:\\ 0\\.024709952121274022\ \(0\)\
\-\ distant\\:\\ 0\\.023975370324410595\ \(0\)\
\-\ iv\\:\\ 0\\.02248864137592135\ \(0\)\
\-\ protocol\\:\\ 0\\.02209620537879996\ \(0\)\
\-\ biopsy\\:\\ 0\\.021863172415649716\ \(0\)\
\-\ patients\\:\\ 0\\.02126514037851948\ \(0\)\
\-\ darkened\\:\\ 0\\.021191150057611775\ \(0\)\
\-\ \\-stage\\:\\ 0\\.021191150057611775\ \(0\)\
\-\ advanced\\-stage\\:\\ 0\\.021191150057611775\ \(0\)\
\-\ 217\\,440\\:\\ 0\\.021191150057611775\ \(0\)\
\-\ 40\\,580\\:\\ 0\\.021191150057611775\ \(0\)\
\-\ 45\\-55\\.\\:\\ 0\\.021191150057611775\ \(0\)\
\-\ erysipeloid\\:\\ 0\\.021191150057611775\ \(0\)\
\-\ mass\\.\\:\\ 0\\.021191150057611775\ \(0\)\
\-\ advanced\\:\\ 0\\.02102339984363549\ \(0\)\
\-\ metastatic\\:\\ 0\\.02068374426553933\ \(0\)\
\-\ women\\:\\ 0\\.01996191985506938\ \(0\)\
\-\ spread\\:\\ 0\\.019872053830972493\ \(0\)\
\-\ invasion\\:\\ 0\\.019783836818144624\ \(0\)\
\-\ non\\-inflammatory\\:\\ 0\\.019524930873573446\ \(0\)\
\-\ brawny\\:\\ 0\\.019524930873573446\ \(0\)\
\-\ iii\\:\\ 0\\.019286045092467508\ \(0\)\
\-\ tumor\\:\\ 0\\.019156079823180877\ \(0\)\
\-\ dimpling\\:\\ 0\\.01855025513292882\ \(0\)\
\-\ streaking\\:\\ 0\\.01855025513292882\ \(0\)\
\-\ basically\\:\\ 0\\.01855025513292882\ \(0\)\
\-\ peau\\:\\ 0\\.01855025513292882\ \(0\)\
\-\ orange\\:\\ 0\\.01855025513292882\ \(0\)\
\-\ lactating\\:\\ 0\\.01855025513292882\ \(0\)\
\-\ misdiagnosed\\:\\ 0\\.017858711689535116\ \(0\)\
\-\ by\\:\\ 0\\.017101813740923975\ \(0\)\
\-\ 1\\-5\\:\\ 0\\.01688403594889049\ \(0\)\
\-\ t7\\:\\ 0\\.016513481430074965\ \(0\)\
\-\ induration\\:\\ 0\\.016513481430074965\ \(0\)\
\-\ mitotic\\:\\ 0\\.016192492505496786\ \(0\)\
\-\ neoadjuvant\\:\\ 0\\.015909360208245862\ \(0\)\
\-\ lethal\\:\\ 0\\.015909360208245862\ \(0\)\
\-\ facilitate\\:\\ 0\\.015909360208245862\ \(0\)\
\-\ thoracic\\:\\ 0\\.01583681493319352\ \(0\)\
\-\ classic\\:\\ 0\\.015741609994269577\ \(0\)\
\-\ nih\\:\\ 0\\.01565608973791455\ \(0\)\
\-\ u\\.s\\:\\ 0\\.01565608973791455\ \(0\)\
\-\ hallmark\\:\\ 0\\.01565608973791455\ \(0\)\
\-\ early\\:\\ 0\\.015024802738665567\ \(0\)\
\-\ figures\\:\\ 0\\.014526273321458455\ \(0\)\
\-\ create\\:\\ 0\\.014526273321458455\ \(0\)\
\-\ present\\:\\ 0\\.013918332360084237\ \(0\)\
\-\ it\\:\\ 0\\.01385227200384387\ \(0\)\
\-\ tends\\:\\ 0\\.013551597580813828\ \(0\)\
\-\ spine\\:\\ 0\\.013529343971179558\ \(0\)\
\-\ 1\\/3\\:\\ 0\\.013359187225829365\ \(0\)\
\-\ warm\\:\\ 0\\.013096688927836596\ \(0\)\
\-\ definition\\:\\ 0\\.013015194813231592\ \(0\)\
\-\ mammograms\\:\\ 0\\.013015194813231592\ \(0\)\
\-\ consisting\\:\\ 0\\.01293637312375325\ \(0\)\
\-\ while\\:\\ 0\\.012926198268520738\ \(0\)\
\-\ approximately\\:\\ 0\\.012710662627671072\ \(0\)\
\-\ diffuse\\:\\ 0\\.012437535674881322\ \(0\)\
\-\ mastectomy\\:\\ 0\\.012206367321353677\ \(0\)\
\-\ cellulitis\\:\\ 0\\.012206367321353677\ \(0\)\
\-\ differentiate\\:\\ 0\\.012094540360692877\ \(0\)\
\-\ t4\\:\\ 0\\.012040519072586969\ \(0\)\
\-\ died\\:\\ 0\\.012040519072586969\ \(0\)\
\-\ when\\:\\ 0\\.011766015565461566\ \(0\)\
\-\ outpatient\\:\\ 0\\.011692968041791036\ \(0\)\
\-\ ages\\:\\ 0\\.011647179111573022\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.011558137593110644\ \(0\)\
\-\ edge\\:\\ 0\\.011514823877959974\ \(0\)\
\-\ failed\\:\\ 0\\.011472276817624876\ \(0\)\
\-\ look\\:\\ 0\\.011430469743798268\ \(0\)\
\-\ rapidly\\:\\ 0\\.011389377355915335\ \(0\)\
\-\ shows\\:\\ 0\\.011295065864081149\ \(0\)\
\-\ emboli\\:\\ 0\\.01111986462004825\ \(0\)\
\-\ death\\:\\ 0\\.011083715876383493\ \(0\)\
\-\ 2004\\:\\ 0\\.01104810268939998\ \(0\)\
\-\ therapy\\:\\ 0\\.010983849981926025\ \(0\)\
\-\ improve\\:\\ 0\\.010944323430108613\ \(0\)\
\-\ right\\:\\ 0\\.010836919580654048\ \(0\)\
\-\ fact\\:\\ 0\\.01081257286161103\ \(0\)\
\-\ returned\\:\\ 0\\.010511699921817745\ \(0\)\
\-\ over\\:\\ 0\\.010459820144903667\ \(0\)\
\-\ \\,\\:\\ 0\\.010411925596818746\ \(0\)\
\-\ invasive\\:\\ 0\\.010321465978166966\ \(0\)\
\-\ d\\:\\ 0\\.010244330606648937\ \(0\)\
\-\ characterized\\:\\ 0\\.01021915921273717\ \(0\)\
\-\ acute\\:\\ 0\\.010143650620704305\ \(0\)\
\-\ consistent\\:\\ 0\\.010073549369380786\ \(0\)\
\-\ 55\\:\\ 0\\.009958388436309116\ \(0\)\
\-\ leading\\:\\ 0\\.009827237031860956\ \(0\)\
\-\ without\\:\\ 0\\.00967314022287577\ \(0\)\
\-\ form\\:\\ 0\\.00960393475567659\ \(0\)\
\-\ is\\:\\ 0\\.009461623674742979\ \(0\)\
\-\ mri\\:\\ 0\\.009438826225551058\ \(0\)\
\-\ local\\:\\ 0\\.00943550311477102\ \(0\)\
\-\ diagnosis\\:\\ 0\\.009433746782598174\ \(0\)\
\-\ thickened\\:\\ 0\\.009211326447735967\ \(0\)\
\-\ adenopathy\\:\\ 0\\.009146353677572699\ \(0\)\
\-\ atypical\\:\\ 0\\.008902717874062393\ \(0\)\
\-\ frequently\\:\\ 0\\.008902717874062393\ \(0\)\
\-\ resolution\\:\\ 0\\.008859662762123618\ \(0\)\
\-\ underlying\\:\\ 0\\.008803429878530574\ \(0\)\
\-\ inflammation\\:\\ 0\\.00873493960017888\ \(0\)\
\-\ compared\\:\\ 0\\.00869476296322277\ \(0\)\
\-\ characteristic\\:\\ 0\\.00869476296322277\ \(0\)\
\-\ and\\/or\\:\\ 0\\.008681518598292555\ \(0\)\
\-\ an\\:\\ 0\\.008521621617437957\ \(0\)\
\-\ done\\:\\ 0\\.008515670349525845\ \(0\)\
\-\ recommended\\:\\ 0\\.008515670349525845\ \(0\)\
\-\ especially\\:\\ 0\\.008454810234178994\ \(0\)\
\-\ pathology\\:\\ 0\\.008407207764717024\ \(0\)\
\-\ patient\\:\\ 0\\.008236460874196038\ \(0\)\
\-\ enlargement\\:\\ 0\\.00815040482328148\ \(0\)\
\-\ progressive\\:\\ 0\\.0081188440265464\ \(0\)\
\-\ in\\:\\ 0\\.008103792887312595\ \(0\)\
\-\ rare\\:\\ 0\\.007976803362195424\ \(0\)\
\-\ referred\\:\\ 0\\.007751277508306831\ \(0\)\
\-\ antibiotics\\:\\ 0\\.00771566432132332\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.007671877206199904\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.007628873444779771\ \(0\)\
\-\ diagnosed\\:\\ 0\\.007553353742295686\ \(0\)\
\-\ intensity\\:\\ 0\\.007424689125911782\ \(0\)\
\-\ they\\:\\ 0\\.007401312804056025\ \(0\)\
\-\ otherwise\\:\\ 0\\.00737816161881333\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.007362850445050157\ \(0\)\
\-\ then\\:\\ 0\\.007310016534668486\ \(0\)\
\-\ palpable\\:\\ 0\\.0072803390447110355\ \(0\)\
\-\ to\\:\\ 0\\.0071862422093771725\ \(0\)\
\-\ was\\:\\ 0\\.007127001362117934\ \(0\)\
\-\ for\\:\\ 0\\.007010655275410723\ \(0\)\
\-\ thickening\\:\\ 0\\.006963039830993634\ \(0\)\
\-\ cause\\:\\ 0\\.006950150544596073\ \(0\)\
\-\ possible\\:\\ 0\\.006918226487702097\ \(0\)\
\-\ first\\:\\ 0\\.00689298902592753\ \(0\)\
\-\ followed\\:\\ 0\\.006886720844660509\ \(0\)\
\-\ unremarkable\\:\\ 0\\.006800640429524185\ \(0\)\
\-\ radiation\\:\\ 0\\.006740988580678693\ \(0\)\
\-\ showed\\:\\ 0\\.0067351040094319635\ \(0\)\
\-\ between\\:\\ 0\\.006510806577462125\ \(0\)\
\-\ abscess\\:\\ 0\\.006494798663784296\ \(0\)\
\-\ clinical\\:\\ 0\\.006320456250158664\ \(0\)\
\-\ show\\:\\ 0\\.006305663304066409\ \(0\)\
\-\ fat\\:\\ 0\\.006247385391542388\ \(0\)\
\-\ usually\\:\\ 0\\.006237808302564325\ \(0\)\
\-\ as\\:\\ 0\\.006214314932183307\ \(0\)\
\-\ treated\\:\\ 0\\.006148679894432354\ \(0\)\
\-\ \\‚\\Ä\\ô\\:\\ 0\\.006139487354916962\ \(0\)\
\-\ changes\\:\\ 0\\.0058871345582573575\ \(0\)\
\-\ lymphoma\\:\\ 0\\.005870669794205495\ \(0\)\
\-\ abnormal\\:\\ 0\\.005858394808449306\ \(0\)\
\-\ all\\:\\ 0\\.005809912234209834\ \(0\)\
\-\ time\\:\\ 0\\.005801926027017579\ \(0\)\
\-\ ct\\:\\ 0\\.005746652179769438\ \(0\)\
\-\ performed\\:\\ 0\\.005727351757757979\ \(0\)\
\-\ y\\/o\\:\\ 0\\.005689012090912598\ \(0\)\
\-\ are\\:\\ 0\\.005600355156392316\ \(0\)\
\-\ if\\:\\ 0\\.005573902485049605\ \(0\)\
\-\ at\\:\\ 0\\.005566169003998236\ \(0\)\
\-\ significant\\:\\ 0\\.005523671036188037\ \(0\)\
\-\ up\\:\\ 0\\.005523671036188037\ \(0\)\
\-\ signal\\:\\ 0\\.005416044063155719\ \(0\)\
\-\ these\\:\\ 0\\.005345780509514039\ \(0\)\
\-\ bilateral\\:\\ 0\\.00498513877239049\ \(0\)\
\-\ chest\\:\\ 0\\.004915213942445959\ \(0\)\
\-\ 1\\:\\ 0\\.004887803769133911\ \(0\)\
\-\ \\%\\:\\ 0\\.004791637099389442\ \(0\)\
\-\ woman\\:\\ 0\\.004744959008386794\ \(0\)\
\-\ most\\:\\ 0\\.004742392167615568\ \(0\)\
\-\ were\\:\\ 0\\.004664149847812311\ \(0\)\
\-\ this\\:\\ 0\\.004620851987087178\ \(0\)\
\-\ left\\:\\ 0\\.004596659948427475\ \(0\)\
\-\ exam\\:\\ 0\\.0045125815864171595\ \(0\)\
\-\ case\\:\\ 0\\.004494001040546324\ \(0\)\
\-\ have\\:\\ 0\\.004448168457608394\ \(0\)\
\-\ and\\:\\ 0\\.004327139560870636\ \(0\)\
\-\ the\\:\\ 0\\.004320290146988306\ \(0\)\
\-\ treatment\\:\\ 0\\.0041577330759636705\ \(0\)\
\-\ seen\\:\\ 0\\.004059200997758871\ \(0\)\
\-\ within\\:\\ 0\\.003918585116312696\ \(0\)\
\-\ which\\:\\ 0\\.0038344821808715115\ \(0\)\
\-\ of\\:\\ 0\\.0036407437749371384\ \(0\)\
\-\ that\\:\\ 0\\.0035480305974971717\ \(0\)\
\-\ disease\\:\\ 0\\.0033575421663839043\ \(0\)\
\-\ normal\\:\\ 0\\.0032202222466324545\ \(0\)\
\-\ from\\:\\ 0\\.0030443166181591645\ \(0\)\
\-\ \\:\\:\\ 0\\.0027170067692083295\ \(0\)\
\-\ with\\:\\ 0\\.002531340348098576\ \(0\)\
\-\ or\\:\\ 0\\.0024075066080858354\ \(0\)\
\-\ \\.\\:\\ 0\\.002048050159462285\ \(0\)\
\-\ a\\:\\ 0\\.0019067298164355832\ \(0\)\
\-\ \\(\\:\\ 0\\.0017364464573169725\ \(0\)\
\-\ \\)\\:\\ 0\\.0017152348368108296\ \(0\)\
